Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Majedie to benefit as its manager agrees to join Brown Advisory

(Sharecast News) - Majedie Investments said Monday that its manager, Marylebone Partners, has entered into a formal agreement to become part of Brown Advisory, with the deal subject only to regulatory approval. On completion, Majedie said it would receive a cash payment for its 7.5% stake in Marylebone, though the sum would not be material to its net asset value.

At the same time, management fees would be reduced to 0.8% on market capitalisation up to £150m, 0.675% between £150m and £250m, and 0.6% thereafter, compared with the current 0.9%, 0.75% and 0.65% tiers.

Majedie confirmed there would be no change to its investment mandate, philosophy, approach or the decision-making autonomy of the existing management team.

Chair Christopher Getley said the board saw several advantages in the combination.

"In addition to the cash payment and fee reduction, the board sees three further benefits from the combination of Marylebone and Brown Advisory.

"Firstly, that access to Brown Advisory's global research team will deepen the analytical capabilities behind each of Majedie's Liquid Endowment strategies in direct investments, external managers, and special investments.

"Secondly, that collaboration with Brown Advisory's external manager selection teams in London and the US will broaden the opportunity set and strengthen the team's ability to negotiate preferential terms.

"Thirdly, that Brown Advisory's institutional scale will reinforce Marylebone's ability to support Majedie's growth ambitions."

At 0933 BST, shares in Majedie Investments were up 2.83% at 236.51p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.